Document Detail

The therapeutic potential of TRAIL receptor signalling in cancer cells.
MedLine Citation:
PMID:  22126726     Owner:  NLM     Status:  In-Data-Review    
In tumour cells, activation of the apoptotic machinery by death receptor ligands of the tumour necrosis factor (TNF) receptor superfamily of cytokines represents a novel therapeutic strategy. However, systemic treatment of tumours with TNF-α and CD95 ligand may produce severe toxic effects. The tumour necrosis-related apoptosisinducing ligand (TRAIL) is a member of the TNF family capable of inducing apoptosis in a wide variety of cancer cells upon binding to pro-apoptotic receptors, while having no effect on the majority of normal human cells tested. Interestingly, preclinical studies in mice and nonhuman primates showed no systemic cytotoxicity upon injection of either recombinant TRAIL or agonistic TRAIL-receptor antibodies. Furthermore, these treatments have been shown to effectively suppress the growth of a range of tumour xenografts. Although unwanted effects of some TRAIL preparations have been reported in normal cells, the use of TRAIL receptor agonists could represent a suitable approach in cancer therapy. Here, we shall review our current understanding of apoptotic and non-apoptotic TRAIL signalling, the therapeutic potential of TRAIL-based approaches in cancer treatment, and the results of phase 1 and 2 clinical trials with recombinant TRAIL or agonistic TRAIL receptor antibodies, either as monotherapy or in combination with other chemotherapeutic agents.
R Yerbes; C Palacios; A López-Rivas
Related Documents :
2145426 - Long-lasting facilitation of excitatory postsynaptic potentials in the rat hippocampus ...
3252806 - Are spontaneous anti-idiotypic antibodies against anti-acetylcholine receptor antibodie...
874836 - The distribution of alpha-bungarotoxin binding sites of mammalian skeletal muscle devel...
6968276 - Desensitization of the muscarinic receptor of bullfrog atrial muscle.
10401616 - Is increased redox-active iron in alzheimer disease a failure of the copper-binding pro...
18676836 - Muc1 oncoprotein blocks death receptor-mediated apoptosis by inhibiting recruitment of ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico     Volume:  13     ISSN:  1699-3055     ISO Abbreviation:  Clin Transl Oncol     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-11-30     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101247119     Medline TA:  Clin Transl Oncol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  839-47     Citation Subset:  IM    
Centro Andaluz de Biología Molecular y Medicina Regenerativa (CABIMER), Consejo Superior de Investigaciones Científicas, Sevilla, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Colorectal cancer stem cell: a potential therapeutic target.
Next Document:  Real-time intravital imaging of cancer models.